Skip to main content

SunP Biotech

HardwareCherry Hill, New Jersey, USAFounded 2014· One of 1708 Hardware companies tracked by AMPulse

Develops 3D bioprinting systems and bioinks for tissue engineering and drug testing using a patented screw-based extrusion technique.

CEO / Founder
Wei Sun
Team Size
11-50
Stage
Active
Total Funding
$4.3M
Latest Round
Venture Round
Key Investors
Orca M&A Capital

Technology & Products

Key Products

SunP Biotech offers a range of 3D bioprinting systems including ALPHA-CPT1, ALPHA-BP11, ALPHA-CPD1 (desktop/benchtop with HEPA filtration and UV sterilization), and ALPHA-CPM1 (mini cell printer). They also develop bioinks such as SUNP FLOAT, G1 Hydrogel, A1 Hydrogel, S1, and LAP, along with 3D cell culture devices and cell/tissue/organ-on-a-chip solutions.

Technological Advantage

Proprietary screw-based extrusion avoids pneumatic heavy equipment, enabling a more compact and standardized bioprinting workflow.

Differentiation

Value Proposition

Reduces equipment footprint and complexity by replacing pneumatic systems with a patented screw-based extrusion process, ensuring high precision and sterility for tissue engineering.

How They Differentiate

Uses screw-based extrusion instead of pneumatic systems, offering higher precision and a more compact form factor than traditional bioprinters.

Market & Competition

Target Customers

Scientific research labs, higher education, pharmaceutical research

Industry Verticals

Tissue engineering; Drug testing; Organ-on-a-chip; Cancer study

Competitors

CELLINK; RegenHU; Alleviate

Growth & Milestones

Growth Metrics

Estimated annual revenue of $4.7M; Total funding raised $4.3M; 400+ LinkedIn followers; 2 global locations (USA and China)

Major Milestones

ALPHA-CPD1 bioprinter won Silver A’s Design Award 2017-2018

Notable Customers

Columbia University; Tsinghua University

https://sunpbiotech.com

Why this company matters

SunP Biotech develops 3D bioprinting systems and bioinks for tissue engineering and drug testing, using a patented screw-based extrusion technique that replaces the pneumatic systems common in competing platforms. This design reduces equipment footprint and complexity while maintaining high precision and sterility, making it suited for benchtop use in scientific research environments.

The company's product line includes the ALPHA-CPT1, ALPHA-BP11, ALPHA-CPD1 (a desktop model with HEPA filtration and UV sterilization), and the ALPHA-CPM1 mini cell printer. SunP also formulates proprietary bioinks such as SUNP FLOAT, G1 Hydrogel, A1 Hydrogel, S1, and LAP, and offers 3D cell culture devices and organ-on-a-chip solutions. The ALPHA-CPD1 won the Silver A' Design Award in 2017-2018.

Target customers include scientific research labs, higher education institutions, and pharmaceutical R&D groups. Notable users include Columbia University and Tsinghua University. The company collaborates with Drexel University and MedPrin, and is led by CEO Wei Sun, a founding president of the International Society of Biofabrication and editor-in-chief of the journal Biofabrication.

SunP Biotech competes with CELLINK, RegenHU, and Alleviate. Its screw-based extrusion approach offers a more compact and standardized workflow than pneumatic alternatives, but the company remains relatively small with estimated annual revenue of $4.7 million and total disclosed funding of $4.3 million from Orca M&A Capital. The key open question is whether its technology can scale beyond academic research into commercial tissue manufacturing.